Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Among authors: xiao s. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination.
Kappos L, Cohan S, Arnold DL, Robinson RR, Holman J, Fam S, Parks B, Xiao S, Castro-Borrero W. Kappos L, et al. Among authors: xiao s. Ther Adv Neurol Disord. 2021 Feb 26;14:1756286420987941. doi: 10.1177/1756286420987941. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 33737954 Free PMC article.
Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
Chang I, Kappos L, Giovannoni G, Calabresi PA, Sandrock A, Cheng W, Xiao S, Riester K, Belachew S, Deykin A, Zhu B. Chang I, et al. Among authors: xiao s. Mult Scler. 2022 Dec;28(14):2263-2273. doi: 10.1177/13524585221114997. Epub 2022 Sep 21. Mult Scler. 2022. PMID: 36131595 Free PMC article. Clinical Trial.
Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE.
Hupperts R, Gasperini C, Lycke J, Ziemssen T, Feys P, Xiao S, Acosta C, Koster T, Hobart J. Hupperts R, et al. Among authors: xiao s. Ther Adv Neurol Disord. 2022 May 18;15:17562864221090398. doi: 10.1177/17562864221090398. eCollection 2022. Ther Adv Neurol Disord. 2022. PMID: 35601756 Free PMC article.
Practice of standardization of CLSI M45 A3 antimicrobial susceptibility testing of Infrequently Isolated or Fastidious Bacteria strains isolated from blood specimens in Guangdong Province 2017-2021.
He N, Yang X, Haque A, Chen J, Guo Y, Li J, Yao L, Zhuo C, Wang J, Wang Y, Li M, Lin Y, Xiao S, Zhuo C. He N, et al. Among authors: xiao s. Front Microbiol. 2024 Apr 29;15:1335169. doi: 10.3389/fmicb.2024.1335169. eCollection 2024. Front Microbiol. 2024. PMID: 38741731 Free PMC article.
7,121 results